Twist Bioscience expands offering of synthetic SARS-CoV-2 RNA controls for NGS diagnostics

In March, Twist launched two fully synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2.

Last week, Twist announced the addition of four new synthetic SARS-CoV-2 RNA Controls for the development, verification, and ongoing validation of diagnostic tests. The controls include new variants of SARS-CoV-2, the virus that causes COVID-19, expanding the genetic diversity of synthetic controls including common mutations found in varying global geographical regions.

These controls continue to be included in many different assays worldwide and can be used to determine the limit of detection, monitor day-to-day test variations and are included on the U.S. Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2.

The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified. For customers interested in alternative variants of SARS-CoV-2, Twist can provide custom controls and also plans to launch additional positive controls in June to continue to address the evolution of the virus and ongoing testing requirements as states and countries begin to re-open. All RNA synthetic controls are anticipated to be delivered within two weeks of ordering.

For more information on the Twist Synthetic SARS-CoV-2 RNA controls, please visit:

Source – BusinessWire

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.